We are live on ! Find out more
TVRD

Tvardi Therapeutics
TVRD

60 hedge funds and large institutions have $112M invested in Tvardi Therapeutics in 2015 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 26 increasing their positions, 11 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

136% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 11

100% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 4

8% more capital invested

Capital invested by funds: $104M → $112M (+$8.65M)

7% more funds holding

Funds holding: 56 → 60 (+4)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
60
Holders Change
+4
Holders Change %
+7.14%
% of All Funds
1.6%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
8
Increased
26
Reduced
11
Closed
4
Calls
$3K
Puts
–
Net Calls
+$3K
Net Calls Change
+$3K

Top Buyers

Rank Fund Capital Flow
1
TC
TFS Capital
Pennsylvania
+$3.69M
2
Renaissance Technologies
Renaissance Technologies
New York
+$2.62M
3
OM
Opaleye Management
Massachusetts
+$2.47M
4
Millennium Management
Millennium Management
New York
+$1.98M
5
CPM
Chesapeake Partners Management
Maryland
+$955K

Top Sellers

Rank Fund Capital Flow
1
DPA
Devon Park Associates
-$5.84M
2
HP
Harbourvest Partners
Massachusetts
-$672K
3
Wellington Management Group
Wellington Management Group
Massachusetts
-$595K
4
JP Morgan Chase
JP Morgan Chase
New York
-$437K
5
HLA
Hamilton Lane Advisors
Pennsylvania
-$210K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCP
1
Rho Capital Partners
New York
$26.8M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$11.7M – – –
Franklin Resources
3
Franklin Resources
California
$6.14M – – –
DPA
4
Devon Park Associates
$5.99M -$5.84M -15,439 -48%
DM
5
Deerfield Management
New York
$4.76M – – –
TAM
6
Tiverton Asset Management
Delaware
$4.64M +$264K +697 +6%
BFA
7
BlackRock Fund Advisors
California
$4.48M +$299K +791 +7%
TC
8
TFS Capital
Pennsylvania
$4.42M +$3.69M +9,752 +396%
Wellington Management Group
9
Wellington Management Group
Massachusetts
$3.38M -$595K -1,572 -14%
OM
10
Opaleye Management
Massachusetts
$3.17M +$2.47M +6,528 +294%
CWG
11
C WorldWide Group
Denmark
$2.8M +$705K +1,862 +32%
WSA
12
Wall Street Associates
California
$2.78M -$114K -300 -4%
JP Morgan Chase
13
JP Morgan Chase
New York
$2.76M -$437K -1,155 -13%
Renaissance Technologies
14
Renaissance Technologies
New York
$2.74M +$2.62M +6,914 +1,041%
T. Rowe Price Associates
15
T. Rowe Price Associates
Maryland
$2.55M – – –
CPM
16
Chesapeake Partners Management
Maryland
$2.52M +$955K +2,524 +57%
Vanguard Group
17
Vanguard Group
Pennsylvania
$2.33M +$596K +1,574 +32%
Millennium Management
18
Millennium Management
New York
$2.25M +$1.98M +5,227 +525%
Jennison Associates
19
Jennison Associates
New York
$2.25M +$7.19K +19 +0.3%
California Public Employees Retirement System
20
California Public Employees Retirement System
California
$1.57M – – –
SKK
21
Shepherd Kaplan Krochuk
Massachusetts
$1.37M +$274K +724 +24%
TA
22
Teachers Advisors
New York
$1.18M – – –
State Street
23
State Street
Massachusetts
$959K -$39K -103 -4%
Deutsche Bank
24
Deutsche Bank
Germany
$858K +$772K +2,041 +615%
Northern Trust
25
Northern Trust
Illinois
$641K – – –
1
2 3

TVRD Hedge Fund Activity: Q1 2015 in Review

60 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q1 2015, worth a combined $112M — up 8.4% from $104M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new TVRD positions and 4 closed out — a net gain of 4 holders — while 26 added to existing stakes and 11 trimmed.

The largest buyer was TFS Capital, adding an estimated $3.69M. The largest seller was Devon Park Associates, cutting an estimated $5.84M.

  • 60 institutional investors held Tvardi Therapeutics (TVRD) as of Q1 2015, up from 56 in Q4 2014.
  • Funds reported $112M of Tvardi Therapeutics stock for Q1 2015, up 8.4% quarter-over-quarter.
  • 8 funds opened new Tvardi Therapeutics positions in Q1 2015 and 4 closed out, a net change of +4 holders.
  • The largest Tvardi Therapeutics buyer in Q1 2015 was TFS Capital, an estimated $3.69M added.
  • The largest Tvardi Therapeutics seller in Q1 2015 was Devon Park Associates, an estimated $5.84M sold.

Based on aggregated 13F filings for Q1 2015.